Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

Article Details

Citation

Copy to clipboard

Michaelides MR, Dellaria JF, Gong J, Holms JH, Bouska JJ, Stacey J, Wada CK, Heyman HR, Curtin ML, Guo Y, Goodfellow CL, Elmore IB, Albert DH, Magoc TJ, Marcotte PA, Morgan DW, Davidsen SK

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

Bioorg Med Chem Lett. 2001 Jun 18;11(12):1553-6.

PubMed ID

11412979 [ View in PubMed

]

Abstract

A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide	Stromelysin-1	IC 50 (nM)	57	N/A	N/A	Details